Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor

NCT00940589 is registered in ClinicalTrials.gov with Neurim Pharmaceuticals Ltd. as lead sponsor.

NCT NCT00940589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00940589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Lead sponsor
Neurim Pharmaceuticals Ltd.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
May 31, 2013
Enrollment
73 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, sleep disorder